Results 61 to 70 of about 7,761,818 (273)

Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review

Diabetology
Metabolic syndrome (MetS) presents a significant global health challenge, characterized by a cluster of metabolic alterations including obesity, hypertension, insulin resistance/dysglycemia, and atherogenic dyslipidemia.
Sandra Knežević, Francesca Filippi-Arriaga, Andrej Belančić, Tamara Božina, Jasenka Mršić-Pelčić, Dinko Vitezić   +5 more
doaj   +1 more source

A cellular genetics approach identifies gene-drug interactions and pinpoints drug toxicity pathway nodes

Frontiers in Genetics, 2014
New approaches to toxicity testing have incorporated high-throughput screening across a broad-range of in vitro assays to identify potential key events in response to chemical or drug treatment.
Oscar Takeo Suzuki, Amber eFrick, Bethany B Parks, O. Joseph eTrask Jr., Natasha eButz, Brian eSteffy, Emmanuel eChan, David K Scoville, Eric eHealy, Cristina eBenton, Patricia E McQuaid, Russell S Thomas, Tim eWiltshire   +12 more
doaj   +1 more source

Comparing methods for drug–gene interaction prediction on the biomedical literature knowledge graph: performance versus explainability

BMC Bioinformatics, 2023
This paper applies different link prediction methods on a knowledge graph generated from biomedical literature, with the aim to compare their ability to identify unknown drug-gene interactions and explain their predictions.
Fotis Aisopos, Georgios Paliouras
doaj   +1 more source

Microbiome−host proteostasis crosstalk—An emerging perspective on mechanisms and interventions toward healthy longevity

FEBS Letters, EarlyView.
Proteostasis and the gut microbiota play a key role in shaping host physiology. Microbiota‐derived metabolites, vitamins, and RNA modulate host proteostasis. Findings from model systems, including C. elegans, indicate microbes can either stabilize or disrupt host proteostasis.
Abhishek Anil Dubey, Maria Ermolaeva
wiley   +1 more source

Pharmacogenomic network analysis of the gene-drug interaction landscape underlying drug disposition

Computational and Structural Biotechnology Journal, 2020
In recent decades the identification of pharmacogenomic gene-drug associations has evolved tremendously. Despite this progress, a major fraction of the heritable inter-individual variability remains elusive.
Yitian Zhou, Volker M. Lauschke
doaj   +1 more source

Design and analysis strategies for robust microbiome ageing research

FEBS Letters, EarlyView.
The gut microbiome changes with age and associates with age‐related morbidity and mortality, establishing it as a potential biomarker and intervention target for ageing. Realising this potential requires methodological rigour, yet distinguishing biological signals from methodological artefacts remains challenging across cohorts. This review provides an
Mark Olenik, İsmail Güderer, Yi Wang, Tayyaba Alvi, Prasoon Pandey, Handan Melike Dönertaş   +5 more
wiley   +1 more source

Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues

Journal of Pharmacy and Bioallied Sciences, 2014
Dendrimers are the emerging polymeric architectures that are known for their defined structures, versatility in drug delivery and high functionality whose properties resemble with biomolecules.
Kanika Madaan, Sandeep Kumar, Neelam Poonia, Viney Lather, Deepti Pandita   +4 more
doaj   +1 more source

Investigating transcription factor dynamics in health and disease using FRAP

FEBS Letters, EarlyView.
FRAP analysis of GFP‐tagged transcription factors reveals how molecular mobility and target engagement change in response to drug treatment. By combining live‐cell imaging, quantitative model fitting, and statistical analysis, this approach uncovers transcription factor dynamics linked to disease mechanisms, providing a powerful framework for ...
Kannan Govindaraj, Carolina Vazquez Garzon, Jose Joaquin Velasco, Janine N. Post   +3 more
wiley   +1 more source

Novel network pharmacology methods for drug mechanism of action identification, pre-clinical drug screening and drug repositioning [PDF]

, 2011
The high rates of failure in oncology drug clinical trials highlight the problems of using pre-clinical data to predict the clinical effects of drugs. Here we present two methodology innovations on network pharmacology modeling.
Jianghui Xiong
core   +1 more source

Investigating drug–target interactions in frontotemporal dementia using a network pharmacology approach

Beni-Suef University Journal of Basic and Applied Sciences, 2021
Background Frontotemporal dementia (FTD) is the second most common type of dementia in individuals aged below 65 years with no current cure. Current treatment plan is the administration of multiple medications.
Archana Balasubramanian, Raksha Sudarshan, Jhinuk Chatterjee   +2 more
doaj   +1 more source